More News! For those who want to keep up with everything

mereo biopharma brittle bone disease osteogenesis imperfecta

More News! 11 Nov 2019

Mereo BioPharma’s Brittle Bone Disease Drug Stumbles in Phase II

The lead drug of the UK company Mereo BioPharma has achieved mixed results in a phase IIb trial in adults with the genetic condition osteogenesis imperfecta, also known as brittle bone disease. Mereo tested different doses of its antibody drug in 112 adults with osteogenesis imperfecta in a 12-month phase IIb trial. The drug failed […]

November 11, 2019 - 2 minutesmins - By Jonathan Smith

More News! 7 Nov 2019

Avantium Builds 10-Ton Demonstration Plant to Produce Bioplastics

The Dutch bioplastics company Avantium has opened a demonstration plant capable of producing 10 tons per year of mono-ethylene glycol (MEG), a compound used to make plastics, using plants as the starting material. Construction of Avantium’s plant began at Chemie Park Delfzijl, the Netherlands, last year. The plant will extract carbohydrates from agricultural waste and […]

November 7, 2019 - 2 minutesmins - By Jonathan Smith

More News! 28 Oct 2019

UK Company Synthesizes Long DNA Molecules with 85% Accuracy

The UK biotech Camena Bioscience has proven it can synthesize long DNA molecules with more accuracy than traditional chemical synthesis. Camena tested its technology’s ability to accurately synthesize DNA molecules with a length of 300 nucleotides — the building blocks of DNA. Using Camena’s technology, 85% of the synthesized DNA molecules were accurate to the […]

October 28, 2019 - 2 minutesmins - By Jonathan Smith

More News! 17 Oct 2019

Sofinnova Partners Raises €333M for its Newest Life Sciences-Focused Fund

Sofinnova Partners, Europe’s largest VC focused on life sciences, has raised €333M to fund early-stage healthcare companies, bringing the total capital managed by the firm to €2B. Sofinnova Partners aims to invest around two-thirds of the new fund, called Sofinnova Capital IX, in European life science companies. The other third will be invested globally, with […]

October 17, 2019 - 2 minutesmins - By Jonathan Smith

More News! 11 Oct 2019

RNA Therapy Improves Vision in Untreatable Genetic Blindness

A phase I/II trial run by the Dutch company ProQR has found that its RNA therapy could significantly improve the vision of people with Leber’s congenital amaurosis, a rare genetic disease for which there is no treatment. The RNA drug, called sepofarsen, is designed to treat people with a specific mutation in a gene […]

October 11, 2019 - 3 minutesmins - By Clara Rodríguez Fernández

More News! 9 Oct 2019

Novo Nordisk and Bluebird Bio to Treat Hemophilia with Gene Editing

The Danish big pharma Novo Nordisk has joined forces with the US gene therapy company bluebird bio to develop next-generation gene editing treatments for hemophilia. The collaboration will last for three years and has the goal of developing a gene therapy that can permanently treat hemophilia A, a genetic disease causing uncontrolled bleeding. Novo Nordisk […]

October 9, 2019 - 1 minutemin - By Jonathan Smith

aleph farms lab grown meat space mission

More News! 8 Oct 2019

Israeli Biotech 3D Prints the First Beef Steak in Space

Hungry astronauts rejoice! Aleph Farms, a company that grows beef steak from animal cells, has grown the first steaks aboard the International Space Station. The Israeli biotech’s experiment is the first proof that meat can be grown in outer space. Aleph Farms created the meat using a 3D bioprinter developed by the Russian company 3D […]

October 8, 2019 - 3 minutesmins - By Jonathan Smith

More News! 7 Oct 2019

UK Biotech Launches with €30M Series A to Treat Autoimmune Disease

MiroBio has spun out of the University of Oxford with a Series A round of €30M (£27M) to develop treatments for autoimmune diseases that don’t disrupt the immune system as a whole. The big Series A round accompanying MiroBio’s launch was co-led by the university’s investor partner Oxford Sciences Innovation and the US investor Samsara […]

October 7, 2019 - 2 minutesmins - By Jonathan Smith

More News! 2 Oct 2019

Engineered Crop Plants Produce Fat Molecules for Formula Milk

A team from the Rothamsted Research center, UK, has developed plants capable of mass-producing fat molecules resembling those in human breast milk. The scientists modified the way a type of oilseed plant generates fat molecules by introducing a mutation that changed the location within the cell of an enzyme responsible for processing fat. As a […]

October 2, 2019 - 2 minutesmins - By Jonathan Smith

More News! 23 Sep 2019

AC Immune Gets €28M from Eli Lilly as Alzheimer’s Drug Hits Phase I

AC Immune will receive €27.6M (CHF 30M) from big pharma Eli Lilly as it begins a phase I trial of its first-in-class Alzheimer’s disease drug. This is the first milestone payment in a deal worth up to €1.6B (CHF 1.7B), which Eli Lilly and AC Immune signed to develop drugs for Alzheimer’s and other neurodegenerative […]

September 23, 2019 - 2 minutesmins - By Jonathan Smith

More News! 18 Sep 2019

€15M to Take Swiss Biotech’s Liver Cirrhosis Treatment to Phase II

Versantis has raised a Series B of €14.6M (CHF 16M) to advance its treatment for late-stage liver cirrhosis to a phase IIa trial. The money will finance the completion of an ongoing phase I trial of Versantis’ lead candidate for the condition decompensated liver cirrhosis. Following this, the company will use the funds to launch […]

September 18, 2019 - 3 minutesmins - By Jonathan Smith

More News! 12 Sep 2019

French Biotech to Develop Septic Shock Therapy with €39M Series B

The French company Inotrem has raised €39M to fund an immunotherapy for septic shock, an often deadly condition caused by infections in the bloodstream. Led by the Hong Kong investor Morningside Ventures, the Series B round will finance a phase IIb trial of Inotrem’s lead candidate drug nangibotide, expected to start in November this year. […]

September 12, 2019 - 3 minutesmins - By Jonathan Smith

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us